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Abstract 
Alström Syndrome (ALMS) is a genetic disorder characterized by obesity, 
progressive hearing and vision loss, and insulin resistance in humans.   Variability of 
additional phenotypes exists among patients, often complicating diagnosis of ALMS 
(Marshall et al., 2011).  Postmortem studies of patients with ALMS revealed severe 
fibrosis in multiple organs (Marshall et al., 2011). Currently, there are no known 
treatments for the fibrosis observed in ALMS patients.  The purpose of the studies 
described herein was to examine the effects of losartan, an antifibrotic drug, on 
fibrogenesis and to identify genomic loci that modify ALMS phenotypes in a mouse 
model for ALMS (Alms1
Gt/Gt
). 
A genome wide screen performed in two backcrosses to C57BL/6Ei and Balb/cJ 
mouse strains identified two genetic modifiers in Alms1
Gt/Gt
 mice.  A significant 
quantitative trait locus (QTL) for high density lipoproteins (HDL) was identified on 
chromosome 5 in the backcross to C57BL/6Ei while significant modifying loci for retinal 
degeneration was identified on chromosome 2 in the backcross to Balb/cJ. Further 
analysis with additional progeny may reveal other significant modifiers.  
Histological and chemical analyses of samples from 24-week-old mutant and control 
mice treated with losartan were initiated in this study.   The results of this study may help 
future therapeutic strategies for treating human patients with ALMS.
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Introduction 
 
Alström Syndrome (ALMS) is a rare multiple system genetic disorder (Marshall, 
2005).  Phenotypes associated with this disorder include: obesity, diabetes, retinal 
degeneration, cochlear degeneration, steatosis (the cellular retention of lipids), fibrosis, 
and other variable features such as hypogonadism (Collin et al., 2002).  Most patients do 
not survive past childhood as a result of cardiomyopathies or other complications.  
Current treatments for ALMS focus on these individual phenotypes, however some 
phenotypes do not currently have treatments (Marshall et al., 2011).  For this reason 
further research is required.  Given the complex assembly and variability of phenotypes 
observed in ALMS patients that are associated with mammalian metabolism, computer 
models and models based on lower organisms are inadequate for understanding this 
disease (Hardouin et al., 2000 and Bedell et al., 1997).  Mouse models have many 
characteristics making them well suited for the study of ALMS.  First, mice are higher 
model organisms with many genes that are also found in humans.  Second, their behavior 
and physiology have been well characterized during decades of research.  Third, there are 
numerous issues of practicality.  Mice have a relatively rapid generation time, are 
inexpensive to maintain, and are easy to handle.  One of the world’s leading suppliers of 
laboratory mice, and the location of prominent research in the areas of genetics and 
human disease, is the Jackson Laboratory located in Bar Harbor, Maine.  The mouse 
populations maintained at the Jackson Laboratory consists of thousands of various 
genetic strains that are used as models for numerous human diseases.  The research 
described herein was performed at the Jackson Laboratory. 
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Study Aims 
One aim of this study was to identify the genetic modifiers that influence the various 
disease phenotypes associated with ALMS in the mouse model.  To identify genetic 
modifiers of pathological phenotypes observed as a consequence of the disruption of the 
Alms1 gene, a genome wide scan was performed in backcrossed progeny of Alms1
Gt/Gt
 
mutants from ((C57BL/6J X Balb/cJ) F1 X C57BL/6Ei) and ((C57BL/6Ei X Balb/cJ) F1 
X Balb/cJ) (Nadeau, 2003). In preliminary studies, Alms1
Gt/Gt
 mutants on C57BL/6Ei and 
Balb/cJ backgrounds exhibited different disease phenotype severities.  Retinal 
degeneration was more rapid on Balb/cJ than C57BL/6J backgrounds (Figure 1). 
Additionally, ALT levels differed on both backgrounds (Figure 2).  The genome scan was 
performed to account for any genetic differences that may cause this phenotypic 
variability.  The computer software, Mapmanager QTX, was used to identify putative 
loci, which interact with ALMS1 and may explain some of the clinical variability 
observed in ALMS (Manly et al., 1999 and Marshall, 2005).   
Since there are no known treatments for the severe fibrosis observed in multiple 
organs of patients with ALMS, the effects of various drugs on organ fibrosis in a mouse 
model for ALMS1 were examined.  The inhibition of signaling pathways in the renin-
angiotensin system have been suggested as an effective therapeutic approach for other 
fibrotic disorders (Yoshiji et al., 2001).  Therefore, losartan, a drug capable of blocking 
the binding of angiotensin-II to angiotensin II type 1 receptor (Yoshiji et al., 2001and 
Bader, 2004), was administered to ALMS1
 
mutant mice to determine its effectiveness in 
alleviating fibrosis (Figure 3). Losartan was used in combination with bezafibrate, a drug 
that inhibits free fatty acid composition and promotes beta-oxidation, to diminish high fat 
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levels observed in mutant mice (Figure 4) (Goldenberg et al., 2008).  The identification 
of genetic modifiers and drug treatments for Alström Syndrome may eventually provide 
more treatment options to patients, and provide more information for related diseases 
such as diabetes, obesity, and liver disease. 
Diagnosis 
Diagnosis and treatment of ALMS is difficult because of its shared similarities to 
other disorders, such as the Bardet-Biedl Syndrome (Marshall et al,. 2007), and of the 
differences in onset, progression and absence or presence of the associated phenotypes 
(Marshall et al., 2005).  These phenotypic differences among patients may be due to 
genetic background modifiers as well as the influence of environmental factors.  Blood, 
vision, and auditory tests as well as heart and thyroid assessments may provide 
information regarding the diagnosis of ALMS.  The diagnostic criterion for ALMS 
consists of the presence of some of the cardinal features of the disease and genetic 
testing.  The cardinal features of the syndrome include neurosensory loss, obesity, 
cardiomyopathy, organ fibrosis, steatosis, insulin resistance and its associated 
complications.  Neurosensory loss often manifests at birth with sensitivity to light and 
reduced visual acuity (Marshall et al., 2005). Visual degeneration progresses into 
adolescence at which point most patients are legally blind (Marshall et al., 2005).  
Studies have found degeneration of the retinal pigment epithelium, cone-rod dystrophy, 
weakened vessels, and subcapsular cataracts in patients (Marshall et al., 2005).  Auditory 
impairment often manifests in childhood and may progress to deafness.  Many patients 
also exhibit dilated cardiomyopathy in infancy through childhood, or restrictive 
cardiomyopathy in adolescence through adulthood, which in some cases proves fatal.  
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Hepatic dysfunction, which is often observed, can range from elevated transaminases to 
overt cirrhosis (Marshall et al., 2007).  Liver biopsies showed signs of inflammation and 
steatosis, or abnormal retention of cellular lipids (Marshall et al., 2005).  Pulmonary 
complications include asthma, bronchitis, inflammation, and hypoventilation.  
Postmortem studies in patients with ALMS showed severe fibrosis in multiple organs 
including the heart, lungs, and liver (Marshall et al., 2005).  These phenotypes and the 
approximate age of appearance within the patient are represented in Figure 5. 
Treatment 
Treatment for ALMS is restricted to the individual treatments of its phenotypes.  The 
rates of progression, age of onset, and degree of severity for retinal degeneration, 
cochlear degeneration, hepatic dysfunction, renal dysfunction, and cardiomyopathy have 
not yet been fully elucidated nor have treatments altered their progression (Paisey, 2009).  
However, patient outcomes can be improved with early detection, monitoring, and 
intensive medical intervention (Marshall et al., 2005).  In all cases, retinal degeneration 
progress to total blindness by adolescence or adulthood (Marshall et al., 2007).  Patients 
are given mobility training at an early age, and hearing aids are utilized to help manage 
hearing loss (Marshall et al., 2007).  ALMS patients with type 2 diabetes are restricted to 
low carbohydrate diets to decrease serum glucose and insulin levels (Paisey, 2009).  
Patients with high lipid levels are treated with insulin therapies, dietary restrictions, and 
nicotinic acid to decrease triglyceride synthesis (Jabbar et al., 1998 and Paisey, 2009).  
There are currently no known treatments for systemic fibrosis observed in ALMS 
patients. 
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Alström Syndrome Genetics 
ALMS is a progressive autosomal recessive genetic disease; therefore, the parents of 
afflicted patients must each carry a recessive copy of the allele and pass it on to their 
offspring in order for the disease phenotype to be observed.  The heterozygous carriers of 
the recessive allele do not show any outward signs of the mutation, but genetic testing 
can reveal carriers.  In humans, nonsense or frameshift mutations in exons 8, 10, and 16 
of the ALMS1 gene on chromosome 2, position13 are attributed as the cause of ALMS 
(Hearn et al., 2002).  Although mutations in any of these exons have been linked to 
ALMS, mutations in exons 8 and 16 have been shown to be more frequent (Figure 6).  
Translation of the normal ALMS1 gene results in a 4169 amino acid protein that is 
ubiquitously expressed and found as part of the centrosome (Andersen et al., 2003 and 
Marshall et al., 2011).  
ALMS Mouse Model  
The ALMS mouse model, Alms1
Gt(XH152)Byg
 herein referred to as Alms1
Gt/Gt
, is a 
genetic mouse strain created and maintained at the Jackson Laboratory prior to the start 
of this experiment.  This mouse model was generated by microinjecting embryonic stem 
cells containing a genetrap cassette into the blastocysts of C57BL/6J wild type mice 
(Collin et al., 2005).  The resulting chimeric males were then backcrossed with C57BL/6J 
wild type mice and the resulting progeny were then genotyped to identify wild type 
(Alms1
+/+
) and heterozygous (Alms1
Gt/+
) mice.  Identified heterozygous mice were then 
bred to generate Alms1
Gt/Gt
 mutant mice.  This method of generating Alms1
Gt/Gt
 mice was 
devised as a result of difficulties breeding Alms1
Gt/Gt
 mice due to obesity complications.  
The Alms1
Gt/Gt
 mouse model exhibits similar characteristics of the human disease such as 
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obesity, hepatic disease, hypogonadism, hyperinsulinemia, retinal dysfunction and 
hearing loss (Marshall et al., 2011) (Figure 7).  Due to the gene-trap cassette insertion in 
intron 13 of the Alms1 gene, this mouse mutation results in an aberrant splicing into the 
cassette resulting in a prematurely terminated protein at the 3’ end of the gene (Marshall 
et al., 2011).  This mutation is similar to the most common mutations in human ALMS 
patients, which also results in a prematurely terminated protein, with variable retention of 
function, at the 3’ end of the gene.   
Significance: 
 The hepatic dysfunction observed in ALMS patients shares many characteristics 
that are also common to non-alcoholic fatty liver disease and non-alcoholic 
steatohepatitis (NAFLD/NASH), namely, steatosis, hyperinsulinemia, 
hypertriglyceridemia, inflammation, and fibrogenesis (Matteoni et al., 1999).  Both of 
these diseases, and their individual phenotypes, are more commonly found in developed 
countries where high calorie, sugar, and fat diets are more common (Sanyal, 2002).  It is 
estimated the prevalence of NAFLD in these countries is approximately 20% and that of 
NASH to be approximately 3-5% with both on the rise (Targher et al., 2007).  The 
development of non-alcoholic steatohepatitis (NASH) occurs in approximately 25% of 
patients with non-alcoholic fatty liver disease (NAFLD), a common form of chronic liver 
disease (Targher et al., 2007).  Necroinflammatory changes and pericellular fibrosis 
distinguish NASH, the more severe form of the disease from NAFLD, which is 
associated with visceral obesity and insulin resistance (Matteoni et al., 1999).  Patients 
with NASH are at higher risk for developing advanced fibrosis, cirrhosis and 
hepatocellular carcinoma, for which current treatments—diet, increased physical activity, 
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antioxidants, lipid-lowering agents, and insulin sensitizers—have had little histological 
impact on the liver (Sanyal, 2002).  Currently, the mechanisms that influence the 
transition from NAFLD to NASH are not fully understood.  It is hypothesized that 
hypertriglyceridemia and an associated accumulation of liver triglycerides from a high fat 
diet in conjunction with inflammatory responses to environmental factors and/or a 
genetic predisposition causes the observed fibrogenesis (Wood et al., 2008).  Recent 
studies have identified an increase in transforming growth factor (TGF-ß) and 
procollagen I mRNA levels in diet induced NASH mouse models (Hirose et al., 2007).  
Angiotensin receptor blockers have been shown to delay the progression of hepatic 
fibrosis and also decrease TGF-ß and collagen gene expression.  Losartan, a selective 
angiotensin II type I receptor antagonist, is capable of reducing hepatic fibrosis in certain 
human and animal models (Yokohama et al., 1980).  Studies involving the drug 
bezafibrate have resulted in reduced accumulation of fat and improved diet induced 
insulin resistance (Sasaki et al., 2011).  Due to the similarities between the hepatic 
pathogenesis in NASH/NAFLD and ALMS, the dissection of genetic modifiers of 
hepatosteatosis and fibrosis in the Alms1
Gt/Gt
 mouse model may provide further insight 
into the biochemical pathways involved in both conditions.  Further research into the 
effects of bezafibrate and losartan on the hepatic disease in the Alms1
Gt/Gt
 model will 
provide valuable information leading to treatment options for ALMS, NAFLD/NASH, 
and the phenotypes found in both diseases for human patients. 
 
  
 
 
  
8 
 
Methods 
The experimental methods described herein, excluding routine mouse care, were 
performed by me, under the supervision of Gayle Collin and Dr. Jürgen Naggert.  
Experimental aims and designs were planned prior to my involvement with the project.  
Histological sectioning and DNA sequencing was performed by their respective 
laboratories at The Jackson Laboratory.   
Mouse Care: 
All mice were housed in Dr. Jürgen Naggert’s animal room at Jackson Laboratory 
(Bar Harbor, ME).  Mice were bred and maintained in sterile barrier facilities according 
to Jackson Laboratory institutional animal care and use (ACUC) procedures.  Personnel 
were required to wear sterilized clothing, gloves, shoes, caps, and masks.  Mice were kept 
in microisolator caging with sterilized bedding, irradiated feed, and filtered and acidified 
drinking water.  Mice were transferred to clean cages using disinfected forceps. 
Losartan and Bezafibrate Experimental Design: 
Alms1
Gt/Gt
 mutants and wild type controls were identified by amplification using the 
polymerase chain reaction (PCR) (Collin et al, 2005) on DNA isolated from Proteinase 
K-digested tail snips.  Losartan and bezafibrate were given at sixteen weeks of age for 
eight weeks.  Four experimental trials were constructed.  Trial one served as a control 
group in which Alms1
Gt/Gt
 mutant and control mice did not receive drug treatment.  Trial 
two consisted of Alms1
Gt/Gt
 mutant and control mice treated with losartan.  In trial three, 
Alms1
Gt/Gt
 mutants and controls were treated with both losartan and bezafibrate.  The 
fourth trial consisted of Alms1
Gt/Gt
 mutants and controls treated with bezafibrate. Mice did 
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not exceed five individuals per cage.  Blood plasma draws were taken for all groups prior 
to treatment at sixteen weeks of age, at twenty weeks of age and at twenty-four weeks of 
age.  At twenty-four weeks of age, or after eight weeks of treatment, mice were 
sacrificed, organs removed, and organ histopathology analyzed.   
Drug Administration: 
 Losartan, supplied by Merck & Co. (Whitehouse Station, NJ), was dissolved in 1ml 
UltraPure Distilled Water at a concentration of 0.3 g/ml.  Losartan was further diluted 
with distilled water and administered to mice of all trials at a concentration of 300 mg/L. 
Dosage levels of losartan were based on earlier titration studies in previously published 
mouse studies (Habashi et al., 2006).  Each mouse was estimated to drink 1.3ml /10g 
body weight.  The actual amount of losartan consumed was determined by monitoring the 
volume of water consumed weekly.  Losartan-treated water was changed weekly to 
prevent microbial growth. 
Bezafibrate was administered in irradiated standard food diet at 1g/kg prepared by 
Research Diets (New Brunswick, NJ) such that each animal received 100mg/kg/day. The 
daily dose of bezafibrate per cage was determined by the equation: DD = SD 
(100mg/kg/day) X average body weight (g)/average daily food intake. 
Chemical Analysis: 
Monthly blood plasma draws and body weights were taken to monitor metabolic 
parameters throughout the course of drug treatment.  Blood samples were taken just prior 
to treatment at sixteen weeks of age, at twenty weeks of age, and twenty-four weeks of 
age.  Trans-orbital eye bleeds were performed on mice according to ACUC-approved 
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protocol at the Jackson Laboratory (LAH 92-05).  Blood plasma was isolated by 
centrifugation at 12,000 rpm at 4 C for 5 minutes and sent for chemical analysis at the 
Jackson Laboratory.  HDL, total cholesterol, triglycerides, free fatty acid, ALT, AST, and 
blood glucose levels were assessed using the Beckman Synchron DXC 800 (Beckman 
Coulter, Inc.).   
Insulin (Mouse) High Range ELISAs (ALPCO Immunoassays, Salem, NH) were 
performed according to manufacture’s protocol.  Blood plasma was isolated by 
centrifugation at 12,000 rpm at 4 C for 5 minutes.  Insulin levels were analyzed sixteen, 
twenty, and twenty-four weeks of age for mutant and control mice using a Mouse Insulin 
ELISA kit (ALPCO).  All samples were analyzed in duplicates and the absorbencies 
averaged.  Sample absorbance was measured at a wavelength of 450nm using a 
SpectraMax 190 (Molecular Devices, Inc., Cilicon Valley, CA) in conjunction with 
ALPCO supplied insulin standards. 
Histological Analysis: 
The extent of fibrosis and steatosis was assessed by histological evaluation of Sirius 
Red and Hematoxylin and Eosin (H&E) stained, Bouin’s-fixed liver and kidneys, 
respectively.  After eight weeks of treatment, mice were sacrificed by CO2 euthanasia and 
the eyes, liver and kidneys removed.  The eyes were then fixed overnight in cold 
methanol, acetic acid, and PBS in a 3:1:4 dilution and the liver and kidneys in Bouin’s 
fixative.  The kidneys were then weighed to determine changes in response to fibrosis 
and steatosis.  Fixed tissues were embedded, sectioned, deparaffinated and stained.  
Kidneys and eyes were stained with hematoxylin and eosin, and livers with Sirius Red.  
Images were then taken using a digital microscope camera with a Leica DM LB 
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microscope (Meyer Instruments, Inc., Houston, TX) and comparisons were made 
between control and mutant mice.  Kidneys were imaged to monitor if any further 
changes resulted from the losartan treatment. 
Genomic Modifier Mapping Experimental Design: 
To identify quantitative trait loci (QTL) that may interact with Alms1 to modify the 
ALMS phenotypes, we selected two background strains that carried the Alms1 mutation: 
C57BL/6Ei- Alms1
Gt/Gt
 and Balb/cJ- Alms1
Gt/Gt
.  Two different sets of backcrosses were 
bred: (B6 X Balb- Alms1
Gt/+
)F1 X Balb-Alms1
Gt/+
 and (B6-Alms1
Gt/+
 X Balb)F1 X B6-
Alms1
Gt/+
. Alms1
Gt/Gt
 genotypes were identified upon weaning, as previously described, 
and DNA from homozygous Alms1
Gt/Gt
 mutants were selected for the genome scan.  
Alms1
Gt/Gt
 DNA was amplified by PCR using evenly spaced microsatellite repeat markers 
across the genome.  PCR results were separated based on different backcrosses: (B6 X 
Balb -Alms1
Gt/+
)F1 X Balb-Alms1
Gt/+
 and (B6-Alms1
Gt/+
 X Balb)F1 X B6-Alms1
Gt/+
.  
Mapmanager QTX computer software was then used to identify linkages between 
genotype and phenotype. 
Determination of Alms1 Genotype: 
DNA was isolated from tail snips of (B6-Alms1
Gt/+
 X B6-Alms1
Gt/+
)F2 progeny using 
proteinase K digestion and salt precipitation (Strauss, 1998).  Genotypes of Alms1
Gt/Gt
, 
heterozygous, and homozygous wild type mice were differentiated through amplification 
of isolated DNA with allele-specific primers.  Cycling conditions for genotyping of 
isolated DNAs were as follows: 94°C for 2 min followed by 45 cycles of 94°C for 20 sec, 
54°C for 30 sec, and 72°C for 40 sec.  A final extension was done at 72°C for 7 min.  
PCR reactions were done with two different primer sets for each DNA sample to test for 
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the wild type and mutant alleles.  Reactions took place in a 11 µl volume containing 10X 
PCR reaction buffer (Boehringer Mannheim), isolated genomic DNA, 25 mM MgCl2, 10 
mM dNTPs,  and 0.25U Taq polymerase (Roche).  For testing the wild type allele 10 µM 
primer 13.3F (5’-tgcaattatgcctgcatgc-3’), and 10 µM primer 13.2R(5’-
agccttccccaggtcaac-3’) were added.  For testing the gene trapped allele 10 µM primer 
13.2F(5’-gatcttatgagtcaccatatg-3’) and 10 µM primer En2.4R(5’-aacgggttcttctgttagtcc-3’) 
were added.  DNAs were separated on a 1.5% agarose gel, stained with ethidium 
bromide, and examined under UV light.  The presence or absence of bands from both 
primer sets determined the genotype. 
Genomic Modifier Mapping: 
DNA was isolated from tail snips of (B6 X Balb -Alms1
Gt/+
)F1 X Balb-Alms1
Gt/+
 and 
(B6-Alms1
Gt/+
 X Balb)F1 X B6-Alms1
Gt/+
 backcrossed progeny as described above. 
Alms1
Gt/Gt
 DNAs were amplified with 65 microsatellite repeat markers spaced, on 
average, 20 cM across the genome.  Locations suggestive of linkage with the quantitative 
phenotype were further tested with markers < 20 cM spacing.  Cycling conditions for 
amplification of DNA specified by the microsatellite repeat markers were as follows: 
94°C for 2 min followed by 49 cycles of 94°C for 20 sec, 50°C for 30 sec, and 72°C for 
30 sec.  A final extension was done at 72°C for 7 min.  Reactions took place in a 11 µl 
volume containing 10X PCR reaction buffer (Boehringer Mannheim), isolated genomic 
DNA, 25 mM MgCl2, 10 mM dNTPs, 0.25U Taq polymerase (Roche), and 10 µM of 
forward and reverse primer.  DNAs were separated on a 4% metaphor/agarose gel, 
stained with ethidium bromide, and examined under UV light.  Results were interpreted 
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when compared with C57BL/6Ei and Balb/cJ controls.  DNAs were also sequenced and 
entered into Mapmanager QTX for analysis. 
Statistical Analysis: 
Identification of putative modifying loci was detected using the Mapmanager QTX 
computer software.  Map Manager identifies QTLs through five levels of complexity.  
Associations were made between trait values and genotypes, hypothetical QTLs, 
background modifiers, and composite interval mapping (Manly et al., 1999).  
Permutation tests were then performed using Map Manager. 
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Results 
Interpretation of experimental data was done under the guidance of Gayle Collin.  
Drug Administration: 
Alms1
Gt/Gt
 and control littermates’ body weights and losartan consumption were 
measured over the 8-week experimental period (Figure 9).  Normalized, average body 
weight and data were observed to be proportionally higher for group 1 than group 2; 
group 2 consisted of three mice, one Alms1
Gt/Gt
 and two Alms1
Gt/+
, and group 1 consisting 
of four mice, three Alms1
Gt/Gt
 and one C57BL/6Ei wild type.  Analysis of the data 
indicated the one Alms1
Gt/Gt
 mouse within group 2 was the heaviest mouse in the study by 
approximately 3 grams, and the heaviest mouse within group 2 by approximately 18 
grams.  However, it was the only Alms1
Gt/Gt
 mutant in group 2. 
Chemical analysis: 
To determine whether losartan could influence phenotypes observed in Alms1
Gt/Gt
 
mice, blood samples were taken at 16 weeks and 24 weeks of age, before, after, and 
without treatment with losartan.  Blood serum parameters observed in Alms1
Gt/Gt
 and wild 
type groups both before and after losartan treatment are shown in Table 1.   
Table 1.  Clinical Chemistry Analysis of Losartan Administered Alms1
Gt/Gt
:
 
Parameters controls  
no losartan 
16 weeks 
Alms1Gt/Gt 
no losartan 
16 weeks 
controls  
no losartan 
24 weeks 
Alms1Gt/Gt  
no losartan 
24 weeks 
controls 
losartan 
24 weeks 
Alms1Gt/Gt  
losartan 
24 weeks 
ALT (IU/L) 
Triglycerides(mg/dl) 
HDL (mg/dl) 
Cholesterol (mg/dl) 
41.0±1.53 
142±66.6 
65.6±8.03 
81.0±13.8 
153±48.6 
154±11.2 
95.2±13.4 
107±10.7 
70.6±22.2 
85.0±12.0 
66.7±2.01 
94.4±2.18 
505±78.5 
75.5±19.5 
123±25.4 
141±35.0 
39±7.37 
97.0±22.1 
72.8±14.7 
84.7±16.9 
383±101 
69.5±18.6 
147±18.3 
169±20.6 
Glucose (mg/dl) 
Free fatty acids 
(mEq/L) 
146±10.8 
2.19±0.55 
 
177±17.1 
2.26±.0.39 
182±9.03 
0.89±0.13 
186±31.5 
0.77±0.04 
152±25.2 
1.88±0.33 
208±10.9 
1.88±0.27 
All results are expressed as averages ± standard error of the means.  Values were 
considered statistically significant when the P-value was equal to or less than 0.05.   
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To provide an indicative value of liver damage, ALT levels were measured in all 
mouse groups both before and after losartan treatment.  ALT (alanine transaminase) is an 
enzyme found in the liver and damage to the liver results in a release of ALT into the 
blood.  Over the 8-week treatment period ALT levels increased more than threefold in 
16-week old Alms1
Gt/Gt
 mutants (153±48.6 IU/L, n = 3) when compared with 24-week old 
Alms1
Gt/Gt
 mice (505±78.5 IU/L, n = 4) not treated with losartan (Figure 10).  After 
treatment, 24-week old, losartan-treated Alms1
Gt/Gt
 mice (383±101 IU/L, n= 4) ALT 
levels only increased by 60%, which was 24% less than untreated Alms1
Gt/Gt
 mutants at 
24 weeks of age.  A two-tailed statistical test of equal variance revealed this difference to 
be insignificant (p = 0.326).  Prior to the start of treatment at 16 weeks of age, 
C57BL/6Ei wild type control mice (n= 4) average ALT levels were 41.0±1.53 IU/L.  
Following the 8-week experimental period, C57BL/6Ei mice both treated (39±7.37 IU/L, 
n= 4) and not treated (70.6±22.2 IU/L, n= 4) with losartan did not have any significant 
change in ALT levels. 
In order to track the phenotypic changes within the ALMS mouse model and those in 
response to losartan treatment, triglyceride levels in collected blood samples were 
analyzed (Figure 11).  Results depicted a twofold decrease in triglyceride levels between 
16-week old Alms1
Gt/Gt
 mice (154±11.2 mg/dl, n=4) and 24-week old Alms1
Gt/Gt
 mice 
(75.5±19.5 mg/dl, n= 2) after 8 weeks.  Following treatment with losartan, this decrease 
in triglyceride levels remained unchanged for Alms1
Gt/Gt
 mice at 24 weeks of age 
(69.5±18.6 mg/dl, n= 4).  A two-tailed statistical test of unequal variance revealed these 
changes to be insignificant (p = 0.09).  Triglyceride levels of C57BL/6Ei wild type 
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control mice depicted a similar trend to those of Alms1
Gt/Gt
 mice.  After 8 weeks, 16-week 
old C57BL/6Ei mice (142±66.6 mg/dl, n= 3) triglyceride levels decreased approximately 
40% for both 24-week old mice treated with losartan (69.5±18.6 mg/dl, n =3) and those 
not treated with losartan (75.5±19.5 mg/dl, n= 5).  A two-tailed statistical test of unequal 
variance revealed these changes to be insignificant (p = 0.481). 
HDL (high-density lipoprotein) levels were measured and analyzed in collected blood 
samples throughout the experimental period (Figure 12).  After 8 weeks, HDL levels of 
16-week old Alms1
Gt/Gt
 mice (95.2±13.4 mg/dl, n= 4) increased by 16% when compared 
to 24-week old untreated Alms1
Gt/Gt
 mice (75.5±19.5 mg/dl, n= 2).  This increase was 
doubled to 35% for 24-week losartan treated Alms1
Gt/Gt
 mice (147±18.3 mg/dl, n= 4) 
when compared with 16-week old mutants.  A two-tailed statistical test of unequal 
variance revealed both changes to be insignificant (p = 0.455, and p = 0.067 
respectively).  C57BL/6Ei wild type control HDL levels at 16 weeks (65.6±8.03 mg/dl, 
n= 3), 24 weeks untreated (66.7±2.01 mg/dl, n= 5), and 24 weeks treated (72.8±14.7 
mg/dl, n= 3) were not altered over the course of the experiment. 
Cholesterol levels were also measured to track Alms1
Gt/Gt 
phenotypic changes and to 
determine if the losartan treatment had an effect (Figure 13).  After 8 weeks, cholesterol 
levels were 24% higher for 24-week old untreated Alms1
Gt/Gt
 mice (141±35.0 mg/dl, n= 
2) than 16-week old Alms1
Gt/Gt
 mice (107±10.7 mg/dl, n= 4).  A two-tailed statistical test 
of unequal variance revealed this change to be insignificant (p= 0.498).  Similarly, 
cholesterol levels were demonstrated to be 37% higher for 24-week old Alms1
Gt/Gt
 mice 
(169±20.6 mg/dl, n= 4) when compared to 16-week old mutants.  A two-tailed statistical 
test of unequal variance revealed this change to be significant (p= 0.049).  C57BL/6Ei 
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wild type control cholesterol levels at 16 weeks (81.0±13.8 mg/dl, n= 3), 24 weeks 
untreated (94.4±2.18 mg/dl, n= 5), and 24 weeks treated (84.7±16.9 mg/dl, n= 3) had no 
significant changes over the course of the experiment. 
Because both human patients and the ALMS mouse model exhibit signs of 
hyperglycemia, blood glucose levels were measured (Figure 14).  Prior to the start of 
treatment, 16-week old Alms1
Gt/Gt
 mice glucose levels were 177±17.1 mg/dl (n= 4).  
After 8 weeks, 24-week old Alms1
Gt/Gt
 mice (186±31.5 mg/dl, n= 2) glucose levels were 
5% higher than 16-week old mutants.  Losartan treated 24-week old Alms1
Gt/Gt
 mice 
(208±10.9 mg/dl, n=4) glucose levels increased 15%, but did not significantly differ from 
16-week and 24-week, untreated mice (p= 0.830 and p= 0.179, respectively).  C57BL/6Ei 
controls at 16 weeks of age (146±10.8 mg/dl, n= 3) and 24 weeks of age (152±25.2 
mg/dl, n= 3), treated, did not significantly change over the 8-week period.  However, 
untreated C57BL/6Ei controls at 24 weeks of age (182±9.03 mg/dl, n= 5) exhibited 17% 
higher average glucose levels.  A two-tailed statistical test of unequal variance revealed 
this difference to be insignificant (p = 0.057). 
Free Fatty Acid levels were measured to determine how they were affected by 
losartan treatment (Figure 15).  Prior to the start of treatment, at 16 weeks of age, 
Alms1
Gt/Gt
 mice (2.26±0.39 mEq/L, n= 4) free fatty acid levels were highest but decreased 
66% at 24 weeks of age, untreated (0.77±0.04 mEq/L, n= 2).  A two-tailed statistical test 
of unequal variance revealed this difference to be significant (p = 0.031).  twenty-four-
week old losartan treated Alms1
Gt/Gt
 mice (1.88±0.27 mEq/L, n= 4) free fatty acid levels 
decreased 17% when compared to 16-week old mutants.  A two-tailed statistical test of 
unequal variance revealed this difference to be insignificant (p = 0.464). C57BL/6Ei 
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controls at 16 weeks of age (2.19±0.55 mEq/L, n= 3) decreased 59% at 24 weeks of age, 
and untreated (0.89±0.13 mEq/L, n= 5).  A two-tailed statistical test of unequal variance 
revealed this difference to be insignificant (p = 0.134).  24-week old losartan treated 
Alms1
Gt/Gt
 mice (1.88±0.27 mEq/L, n= 3) free fatty acid levels decreased 14% when 
compared to 16-week old mutants.  A two-tailed statistical test of unequal variance 
revealed this difference to be insignificant (p = 0.655).  The observed pattern of free fatty 
acid levels was the same for both Alms1
Gt/Gt 
and C57BL/6Ei mice. 
Histological Analysis: 
The extent of fibrosis and steatosis was assessed by histological evaluation of liver 
samples in both losartan treated Alms1
Gt/Gt
 and untreated groups (Figure 16).  Liver 
sections of C57BL/6Ei wild type mice exhibited normal hepatocytes with no signs of 
fibrosis or hepatosteatosis (Figure 16a).  Normal hepatocytes were presented as clusters 
of cells with obvious nuclei, organized into 1-cell thick plates, separated by vascular 
channels.  Liver sections of untreated Alms1
Gt/Gt
 mice at one year of age exhibited severe 
fibrosis as well as macro hepatosteatosis (Figure 16b).  Losartan treated mice at twenty-
four weeks of age exhibited micro and macro hepatosteatosis as well as fibrosis (Figure 
16c, 16d).  Micro hepatosteatosis presented as white, clustered, bubble-like areas of the 
hepatocytes, caused by cellular retention of lipids.  Macro hepatosteatosis presented as 
larger, white, singular areas of clustered lipids.  Fibrosis presented as darker stained areas 
within the vascular channels due to increases of collagen in theses areas.  Trials involving 
bezafibrate are still in progress. 
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Genomic Modifier Mapping: 
Various phenotypic data was collected from Alms1
Gt/Gt
 on the C57BL/6Ei and Balb/cJ 
backgrounds (Table 2).  ALT, glucose, and fibrosis levels were more severe in 
C57BL/6Ei backcrossed progeny while outer nuclear layers (outer layers of the retina) 
were fewer in Balb/cJ backcrossed progeny.  Body weight, kidney weight, steatosis, 
insulin, cholesterol, and HDL were also higher in C57BL/6Ei backcrossed progeny, while 
triglycerides and free fatty acids were higher in Balb/cJ backcrossed progeny.   
Table 2.  Clinical Chemistry Analysis of F2- Alms1Gt/Gt Backcross Progeny 
Parameters (B6 X Balb)F1 X Balb 
Backcross 
(B6 X Balb)F1 X B6 
Backcross 
Body Weight (g) 47.2 ± 1.00 52.5 ± 1.48 
Kidney Weight (g) 0.29 ± 0.01 0.35 ± 0.01 
Liver Fibrosis 0.00 ± 0.00 0.89 ± 0.23 
ONL Layers 6.72 ± 0.14 8.72 ± 0.14 
Steatosis 0.96 ± 0.04 1.58 ± 0.15 
Insulin (ng/ml) 110 ± 21.5 150 ± 24.1 
Cholesterol (mg/dl) 137 ± 4.32 156 ± 10.7 
HDL (mg/dl) 112 ± 2.97 131 ± 7.81 
Triglycerides (mg/dl) 287 ± 15.3 136 ± 7.84 
Free fatty acids (mEq/L) 1.79 ± 0.06 1.14 ± 0.04 
ALT (IU/L) 103 ± 10.2 260 ± 46.3 
Glucose (mg/dl) 199 ± 9.36 230 ± 17.9 
Note: Numbers represent averages ± standard error of the means.  Analysis was done for 
32 Balb and 18 B6 backcross progeny.  All mice were at 20 weeks of age.  Liver fibrosis 
was judged on a scale of 0 to 3 with 3 the most severe.  Steatosis was rated on a scale of 0 
to 2 with 2 indicative of macrosteatosis and 1 of microsteatosis. 
 
Utilization of Mapmanager QTX computer software resulted in identification of 
putative modifying loci in the (B6 X Balb)F1 X Balb and (B6 X Balb)F1 X B6 
backcrosses (Table 3).  Reported putative modifying loci were limited by p-values <0.001 
and <0.01.  Genotype markers were omitted from analysis for incomplete data.  However, 
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genotypes were inferred from flanking markers when the genotypes agreed; these 
markers were not treated as missing data (Manly et al., 1999).  A chromosome map 
showing relative locations of the genomic modifiers is shown in Figure 17. 
Table 3. Positions and phenotypic attributes of QTLs for HDL, ALT, insulin, body 
weight, free fatty acids, fibrosis, and glucose detected in F2- Alms1
Gt/Gt
 Backcrosses 
Backcross Phenotype Chr Position 
(cM) 
Marker p-value Symbol 
(B6 X Balb)F1 X B6 HDL 5 19.7 D5Mit233 0.000048 AhdlB6 
 ALT 4 66.7 D4Mit251 0.00479 Alt1B6 
         4 30.6 D4Mit178 0.00173 Alt2B6 
 Insulin 8 42.6 D8Mit240 0.00134 AinsB6 
 Body weight 4 30.6 D4Mit178 0.00727 AbwB6 
 Free fatty acids 13 47 D13Mit262 0.00659 AffaB6 
 Fibrosis 19 1.1 D19Mit109 0.00112 AfB6 
(B6 X Balb)F1 X 
Balb 
Retinal 
Degeneration 
2 72.1 D2Mit493 0.00003 ArdB 
 Body weight 1 61.2 D1Mit135 0.00378 Abw1B 
        2 68.9 D2Mit282 0.00557 Abw2B 
 Insulin 15 29.5 D15Mit156 0.00342 AinsB 
 ALT 3 57.9 D3Mit44 0.00518 AltB 
 Glucose 8 12 D8Mit4 0.00966 AgluB 
Note: Position (cM) of marker locus (Mouse Genome Database) with peak lod score. 
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Discussion 
 Alström Syndrome (ALMS) is a clinically progressive genetic disorder characterized 
by vision and hearing loss, obesity, steatosis, fibrosis, insulin resistance and its associated 
complications.  Currently, there are few treatments for these phenotypes.  The experiment 
described herein sought to address the hepatosteatosis and fibrosis phenotypes using the 
previously created Alms1
Gt/Gt
 mouse model.   
In this study, losartan treatment of Alms1
Gt/Gt
 mice, beginning at 16 weeks of age and 
continuing for 8 weeks, had little effect on phenotypic improvement.  The increase in 
ALT levels (which are indicative of liver damage) observed over the 8-week period for 
both treated and untreated Alms1
Gt/Gt
 mice was likely a result of the condition worsening 
over time.  The small decrease in ALT levels within treated Alms1
Gt/Gt
 mice when 
compared to untreated Alms1
Gt/Gt
 mice may have been a result of the losartan treatment.  
However, because the difference is not significant it cannot be concluded that the 
difference was a result of the treatment.  Triglycerides were observed to be the highest in 
16-week old mice of all groups and to have decreased over the 8-week period for both 
treated and untreated wild type and Alms1
Gt/Gt
 mice.  Because this decrease was seen in 
both Alms1
Gt/Gt
 and wild type mice, as well as treated and untreated mice, it can be 
assumed that it had nothing to do with the progression of the Alms1
Gt/Gt
 phenotype or 
losartan.  Possible reasons for this change may be found within the mouse lifecycle or it 
may be due to the small number of mice in this study.  Further research with a greater 
number of mice would provide more information.  HDL and cholesterol levels were 
observed to have the same pattern of change over the 8-week period for Alms1
Gt/Gt
 mice.  
This was not unexpected because of the relationship between HDL and cholesterol.  HDL 
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is used to transport the hydrophobic molecule cholesterol throughout the aqueous 
environment of the body (Kwiterovich, 2000).  Therefore, any increase in cholesterol 
would likely trigger an increase in HDL synthesis for the purpose of transport.  It was 
interesting to note that both HDL and cholesterol levels in Alms1
Gt/Gt
 mice increased over 
the 8-week period and were highest in those treated with losartan.  Previous studies have 
shown losartan to slightly increase HDL and cholesterol in human patients with 
hypertension and type 2 diabetes (Lozano et al., 2001).  In addition, other studies have 
found that increases in cholesterol suppress cellular TGF-  responsiveness in vascular 
cells (Chen et al., 2007).  This may suggest that cholesterol has some protective benefits 
against TGF-  and perhaps fibrosis in Alms1
Gt/Gt
 mice and human ALMS patients.  
Glucose levels were not observed to have changed much as a result of losartan treatment.  
This was not unexpected as there is no data suggesting losartan has any affect on glucose 
levels.  Glucose levels of treated 24-week old Alms1
Gt/Gt
 mice were observed to be 
slightly higher than other Alms1
Gt/Gt
 mice and wild types.  Because all measured glucose 
levels are approximately the same, it is likely that any differences among groups are the 
result of low numbers of mice in the study.  Observed free fatty acid levels did not differ 
between Alms1
Gt/Gt
 mice and their wild type counterparts.  This suggests that the 
genotype (either Alms1
Gt/Gt
 or wild type) did not influence free fatty acid levels.  Free 
fatty acid levels did differ between experimental groups.  Free fatty acid levels were 
highest for 16-week old mice and lowest for 24-week old untreated mice.  This suggests 
that losartan had an effect on free fatty acid levels.  Previous studies have shown 
increases in free fatty acids as a result of losartan treatment (Fellmann et al., 2009).  
Further experiments with more mice would be necessary to validate these results.  Tissue 
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analysis of losartan treated Alms1
Gt/Gt
 mice was indistinguishable from untreated 
Alms1
Gt/Gt
 mice.  This result was not unexpected due to the observed high ALT levels, 
which are correlated to liver damage, and did not significantly differ between treated and 
treated Alms1
Gt/Gt
 mice.  Longer treatment periods may see an improvement in 
histological samples. 
 Bezafibrate is a drug that has been shown to inhibit free fatty acid composition and 
promote beta-oxidation.  Bezafibrate treatment of Alms1
Gt/Gt
 mice is in progress.  Other 
fatty acid oxidation enhancers such as Wy14,643 have been shown to reduce 
microsteatotic and macrosteatotic change in foz/foz mice, which are phenotypically 
similar to Alms1
Gt/Gt
 mice (Larter et al., 2012).  In these studies, steatotic improvements 
were seen following 10 days of treatment.  In the present study, treatment with 
bezafibrate will continue in conjunction with losartan.   
In most cases, human diseases are not treated until the phenotypic symptoms of the 
disease emerge.  By administering losartan at 16 weeks of age, and after the appearance 
of the ALMS phenotype, treatment was intended to simulate treatment in human ALMS 
patients. Previous studies have identified a correlation between increased transforming 
growth factor (TGF-ß) and increased procollagen I mRNA levels (Kagami et al, 1994).  
TGF-ß is known to influence other biochemical pathways that regulate cell division, heart 
disease, diabetes and more.  Losartan, a selective angiotensin II type I receptor 
antagonist, has been shown to reduce both TGF-ß and procollagen I mRNA thus 
decreasing hepatic fibrosis in certain human and animal models (Yoshiji et al, 2001).  In 
a preliminary study with Alms1
Gt/Gt
 mice, losartan was administered to mice beginning at 
approximately 3 weeks of age, before development of the ALMS phenotype, and 
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treatment continued until 9 months of age (Collin et al., unpublished).  Analysis of these 
data suggested that losartan significantly lowered ALT levels in treated Alms1
Gt/Gt
 mice 
compared to untreated Alms1
Gt/Gt
 mice.  In the present experiments, results suggested 
losartan had little effect in relieving the fibrosis observed in the Alms1
Gt/Gt
 mouse model.  
Based on the success of previous studies, it is possible that a treatment period of 8 weeks 
is not enough time to observe a significant change.  Studies have shown that losartan 
treatment over a 6-month period significantly lowered pulmonary fibrosis (Habashi et al., 
2006).  In previous studies of Marfan Syndrome, losartan was administered prenatally 
and continued until 10 months of age (Habashi et al., 2006).  Fibrosis was diminished in 
the tissues of these treated mice.   These data suggest prolonged treatment with losartan 
exceeding 2 months of treatment may result in decreased fibrosis in liver samples.  
Currently, there is no singular treatment for ALMS.  This study may help identify 
alternative and less harmful treatments for the multiple phenotypes associated with 
ALMS.  By treating severe phenotypes—fibrosis and steatosis—the onset of systemic 
fibrosis observed in ALMS patients may be prevented or delayed.  Moreover, these 
treatments may extend to other diseases such as NASH where fibrosis and steatosis are 
prevalent. 
Diagnosis and treatment of ALMS are difficult because of the differences in the 
onset, progression and absence or presence of the associated phenotypes (Marshall, 
2005).  These phenotypic differences among patients may be due to genetic background 
modifiers as well as the influence of environmental factors.  Utilization of the Alms1
Gt/Gt
 
mouse model to study ALMS enables a degree of environmental and genetic control 
unreachable in human patients.  Through this control, possible environmental effects can 
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be minimized and genomic modifiers identified.  Several genomic modifiers were 
identified with significance p<0.05.  With the backcross to C57BL/6Ei, significant 
modifying loci were HDL and suggestive loci were ALT, insulin, body weight, free fatty 
acids, and fibrosis. With the backcross to Balb/cJ, significant modifying loci were retinal 
degeneration and suggestive loci were body weight, glucose, ALT and insulin.  Previous 
studies have proposed a modifier for retinal degeneration in the tub/tub mouse model on 
chromosome 2 (Andersen et al., 2003). Alms1
Gt/Gt
 and tub/tub mice are similar 
phenotypically—sharing adult-onset obesity and progressive retinal and cochlear 
degeneration (Collin et al., 2002).  The QTL on chromosome 2 that modifies retinal 
degeneration in the tub/tub mouse lies between chromosomal positions 34.4 and 77.2 cM.  
The QTL on chromosome 2 that modifies retinal degeneration in the Alms1
Gt/Gt
 mouse 
model is located around 72.1cM. These data may indicate that the modifier for retinal 
degeneration may be the same in both tub/tub and Alms1
Gt/Gt
 mice.  A candidate gene 
modifier for Alms1 and Tub may be BBS6/MKKS, which lies within chromosomal 
positions 34.4 and 77.2 cM.  Previous studies have shown that patients with mutations in 
the BBS6 gene have clinical features similar to ALMS and both proteins localize to the 
centrosome (Marshall, 2005).  Identification of significant modifying loci may provide 
more information as to the progression and early detection of phenotypes associated with 
ALMS.  This would require further study to positively associate genotype with 
phenotype. 
Although losartan was shown to reduce the levels of some phenotypic traits 
associated with the Alms1
Gt/Gt
 mouse model, it was also shown to increase others.  While 
these changes were generally insignificant, other studies have shown longer treatment 
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periods starting at an earlier time would improve the degree of changes observed as a 
result of losartan treatment.  Several genomic loci that may influence phenotypic 
observations within Alms1
Gt/Gt
 mice were identified.  These findings, when compiled with 
those from future experiments, may offer ways to identify ALMS progression in human 
patients. 
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Figures 
 
Figure 1:  Background Retinal Degeneration.  Retinal degeneration differed between 
Alms1
Gt/Gt
 C57BL/6Ei and Balb/cJ mice of 24 weeks of age.  Degeneration is more severe 
in Balb/cJ mice (right), which is represented by fewer outer nuclear layers (ONL), and 
thinner outer plexiform (OPL) and rods and cones (IS/OS).  Both the ganglion cell layer 
(GC) and the inner plexiform layer (IPL) are not shown in the C57BL/6Ei retina image 
(left).  Retinal pigment epithelium (RPE) appeared different due to the tendency of black 
eyes in C57BL/6Ei mice and red eyes in Balb/cJ mice.  Images courtesy of Gayle Collin.   
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Figure 2:  Background ALT Levels.  ALT levels differed between Alms1
Gt/Gt
 C57BL/6Ei 
and Balb/cJ mice of the same age.  C57BL/6J mice ALT levels were approximately 
higher than those of Balb/cJ mice.  Image courtesy of Gayle Collin. 
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Figure 3:  Action of Losartan.  The mechanism of action of losartan within the renin-
angiotensin system (RAS).  Angiotensinogen (AGT) produced by the liver is converted to 
angiotensin-I (ATI) by rennin, which is produced in the kidneys (Yoshiji et al., 2001).  
Angiotensin-converting enzyme (ACE) then cleaves ATI to angiotensin-II (ATII).  ATII 
then binds to angiotensin II type 1 receptor (ATR1), which causes a cascading effect that 
induces an increase in the translation of procollagen I mRNA and an increase in fibrotic 
tissue.  Losartan blocks the binding of ATII to ATRI, dampening the cascading effect that 
results in an increase of fibrotic tissue.  Figure adapted from Yoshiji et al., 2001. 
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Figure 4:  Action of Bezafibrate.  Bezafibrate binds with and activates PPAR  
(peroxisome proliferators-activated receptor- ) causing PPAR  to bind and form a 
heterodimer with RXR (retinoid X receptor).  Together both PPAR  and RXR bind 
PPRE (peroxisome proliferator response elements) which influences gene expression.  
Transcription of target genes causes an increase in HDL synthesis and -oxidation and 
causes a decrease in triglycerides (Goldenberg et al., 2008).  Figure adapted from 
Goldenberg et al., 2008. 
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Figure 5:  ALMS Phenotypes, Progression, and Approximated Age of Appearance.  
Phenotypes on blue arrows are known as cardinal features of ALMS, and are present in 
most patients (Marshall et al., 2005).  Variable phenotypes include, but are not limited to, 
those listed on orange arrows (Marshall et al., 2007).  Image adapted from Jan Marshall.   
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Figure 6:  Frequency of Exon Mutations in Human ALMS1.  Genotype examinations of 
105 ALMS patients demonstrated the most frequent mutations were found on exons 8, 
16, and 10 on chromosome 2, position 13.  Mutations have been characterized as 
nonsense or frameshift mutations causing a prematurely terminated protein (Hearn et al., 
2002).  Image courtesy of Gayle Collin. 
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Figure 7: ALMS1 Mutation Phenotypes and Progression in Mice.  Many phenotypes 
observed in human ALMS patients were also seen in the Alms1
Gt/Gt
 mouse model.  Figure 
adapted from Gayle Collin.   
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Figure 8:  Losartan-Treated Water Consumption per Week.  Losartan treated water 
consumption was proportionally similar for group 1 and group 2.  Group 1 consisted of 
four mice, three of which were Alms1
Gt/Gt
 and one was C57BL/6Ei wild type.  Group 2 
consisted of three mice, one of which was Alms1
Gt/Gt
 and two were Alms1
Gt/+
.  Water 
consumption was measured every seven days.  Data were then averaged and normalized 
according to number of Alms1
Gt/Gt
 mutants in each group.   
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Figure 9: Body Weight.  Average body weights of Group 1 were proportionally greater 
than Group 2.  Trial 1 consisted of four mice, three of which were Alms1
Gt/Gt
 and one was 
C57BL/6J wild type.  Trial 2 consisted of three mice, one of which was Alms1
Gt/Gt
 and 
two were Alms1
Gt/+
.  Body weight was measured at 16 weeks of age, 20 weeks of age, 
and 24 weeks of age.  Data were then averaged and normalized according to number of 
Alms1
Gt/Gt
 mutants in each group.  Previous data suggests the volume of water consumed 
is influenced by body weight. 
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Figure 10:  ALT Levels Before and After Losartan Treatment.  Over the 8 week 
experimental period ALT levels increased in both untreated and treated Alms1
Gt/Gt
 mice at 
24 weeks of age.  Average ALT levels are shown for untreated wild type mice at 16 
weeks of age, 24 weeks of age, and treated at 24 weeks of age (n = 3; n = 5; n = 3).  
Average ALT levels are shown for untreated Alms1
Gt/Gt
 mutants at 16 weeks of age, 24 
weeks of age, and treated at 24 weeks of age (n = 4; n = 4; n = 4).  The increase in ALT 
levels for 24-week-old Alms1
Gt/Gt
 mice after losartan treatment was less in comparison to 
untreated Alms1
Gt/Gt
 mice of the same age.  A two-tailed statistical test of equal variance 
revealed this difference to be insignificant (p = 0.326).  Alms1
Gt/Gt
 mice had higher ALT 
levels than their wild type controls.  Wild type controls varied little between groups. 
Error was calculated as standard error of the means. 
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Figure 11:  Triglycerides Before and After Losartan Treatment.  Over the 8-week 
experimental period, triglyceride levels decreased in both untreated and treated Alms1
Gt/Gt
 
mice at 24 weeks of age.  Average triglyceride levels are shown for untreated wild type 
mice at 16 weeks of age, 24 weeks of age, and treated at 24 weeks of age (n = 3; n = 5; n 
= 3).  Average triglyceride levels are shown for untreated Alms1
Gt/Gt
 mutants at 16 weeks 
of age, 24 weeks of age, and treated at 24 weeks of age (n = 4; n = 2; n = 4).  Triglyceride 
levels decreased in 24-week-old ALMS1
Gt/Gt
 mice after losartan treatment in comparison 
to untreated Alms1
Gt/Gt
 mice of the same age.  A two-tailed statistical test of unequal 
variance demonstrated this difference to be insignificant (p = 0.839).  Triglyceride levels 
decreased by approximately 40% in both Alms1
Gt/Gt
 and wild type mice after 24 weeks 
with and without treatment.  A two-tailed statistical test of unequal variance showed the 
difference between untreated controls at 16 and 24 weeks to be insignificant (p = 0.481). 
Error was calculated as standard error of the means. 
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Figure 12:  HDL Before and After Losartan Treatment.  Over the 8-week experimental 
period HDL levels increased in both untreated and treated Alms1
Gt/Gt
 mice at 24 weeks of 
age.  Average HDL levels are shown for untreated wild type mice at 16 weeks of age, 24 
weeks of age, and treated at 24 weeks of age (n = 3; n = 5; n = 3).  Average HDL levels 
are shown for untreated Alms1
Gt/Gt
 mutants at 16 weeks of age, 24 weeks of age, and 
treated at 24 weeks of age (n = 4; n = 2; n = 4).  After 24 weeks-of-age, mice without 
losartan treatment had 35% higher HDL levels than those at 16 weeks of age.  HDL 
levels were approximately 15% higher in 24-week-old Alms1
Gt/Gt
 mice after losartan 
treatment in comparison to untreated Alms1
Gt/Gt
 controls of the same age.  A two-tailed 
statistical test of unequal variance showed this difference to be insignificant (p = 0.525).  
Alms1
Gt/Gt
 mice had higher HDL levels than their wild type controls.  Wild type control 
HDL levels were not affected over the 8-week experimental period. Error was calculated 
as standard error of the means. 
 
 
 
 
 
 
 
 
 
 
 
  
39 
 
 
  
Figure 13:  Cholesterol Before and After Losartan Treatment.  Over the 8-week 
experimental period cholesterol levels increased in both untreated and treated Alms1
Gt/Gt
 
mice at 24 weeks of age.  Average cholesterol levels are shown for untreated wild type 
mice at 16 weeks of age, 24 weeks of age, and treated at 24 weeks of age (n = 3; n = 5; n 
= 3).  Average cholesterol levels are shown for untreated Alms1
Gt/Gt
 mutants at 16 weeks 
of age, 24 weeks of age, and treated at 24 weeks of age (n = 4; n = 2; n = 4).  Cholesterol 
levels increased in 24-week-old ALMS1
Gt/Gt
 mice after losartan treatment in comparison 
to untreated Alms1
Gt/Gt
 controls of the same age.  A two-tailed statistical test of unequal 
variance revealed this difference to be insignificant (p = 0.574). Alms1
Gt/Gt
 mice had 
higher cholesterol levels than their wild type controls.  Wild type control cholesterol 
levels were not affected over the 8-week experimental period. Error was calculated as 
standard error of the means. 
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Figure 14:  Glucose Before and After Losartan Treatment.  Over the 8-week experimental 
period glucose levels increased in both untreated and treated Alms1
Gt/Gt
 mice at 24 weeks 
of age. Average glucose levels are shown for untreated wild type mice at 16 weeks of 
age, 24 weeks of age, and treated at 24 weeks of age (n = 3; n = 5; n = 3).  Average 
glucose levels are shown for untreated Alms1
Gt/Gt
 mutants at 16 weeks of age, 24 weeks 
of age, and treated at 24 weeks of age (n = 4; n = 2; n = 4).  Glucose levels increased in 
24-week-old Alms1
Gt/Gt
 mice after losartan treatment in comparison to untreated 
Alms1
Gt/Gt
 controls of the same age.  A two-tailed statistical test of unequal variance 
demonstrated this difference to be insignificant (p = 0.603).  Alms1
Gt/Gt
 mice had higher 
glucose levels than their wild type controls.  Wild type control glucose levels were 
highest for untreated mice at 24 weeks of age during the 8-week experimental period.  A 
two-tailed statistical test of unequal variance revealed the difference between untreated 
controls at 16 and 24 weeks to be insignificant (p = 0.057). Error was calculated as 
standard error of the means. 
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Figure 15:  Free Fatty Acids Before and After Losartan Treatment.  Over the 8-week 
experimental period free fatty acid levels decreased in both untreated and treated 
Alms1
Gt/Gt
 mice at 24 weeks of age. Average free fatty acid levels are shown for untreated 
wild type mice at 16 weeks of age, 24 weeks of age, and treated at 24 weeks of age (n = 
3; n = 5; n = 3).  Average free fatty acid levels are shown for untreated Alms1
Gt/Gt
 mutants 
at 16 weeks of age, 24 weeks of age, and treated at 24 weeks of age (n = 4; n = 2; n = 4).  
A two-tailed statistical test of unequal variance demonstrated the difference of free fatty 
acid levels between Alms1
Gt/Gt
 mice at 16 and 24 weeks of age to be significant (p = 
0.031).  Free fatty acid levels increased in 24-week-old Alms1
Gt/Gt
 mice after losartan 
treatment in comparison to untreated Alms1
Gt/Gt
 controls of the same age.  A two-tailed 
statistical test of unequal variance revealed this difference to be significant (p = 0.026).  
Alms1
Gt/Gt
 mice had higher free fatty acid levels than their wild type controls.  Wild type 
control free fatty acid levels decreased during the 8-week experimental period.  A two-
tailed statistical test of unequal variance revealed the difference of free fatty acid levels 
between wild type mice at 16 and 24 weeks to be insignificant. Error was calculated as 
standard error of the means. 
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Figure 16:  Liver Histological Analysis for Losartan Study.  Histological analysis of 
treated Alms1
Gt/Gt
 mice at 24 weeks of age exhibited signs of fibrosis.  Images were taken 
of a wild type mouse not treated with losartan at 24 weeks of age (a), an Alms1
Gt/Gt
 mouse 
not treated with losartan at 24 weeks of age (b), and Alms1
Gt/Gt
 mice treated with losartan 
at 24 weeks of age (c and d).  Untreated, 24-week-old mouse (a), exhibited no signs of 
steatosis or fibrosis.  Sections b, c, and d all exhibited signs of fibrosis and both micro 
and macro steatosis.  Fibrosis was most obvious in section d where it was seen as darker 
red spacing between hepatocytes indicated by the blue arrow.  Microsteatosis was seen in 
small white spaces ballooning the hepatocytes as seen in section c, indicated by the black 
arrow.  Macrosteatosis was seen as larger white spaces as seen in section d, indicated by 
the black arrow. 
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Figure 17:  Relative Positions of Genomic Modifiers on Associated Chromosomes.  
Mouse karyotype with the approximated locations of statistically significant modifier loci 
designated by symbol names.  Symbol names were derived by abbreviation of phenotype 
and backcross.  Phenotypes differed based on backcross.  (B6 X Balb)F1 X B6 
backcrosses exhibited fibrosis and (B6 X Balb)F1 X Balb backcrosses exhibited retinal 
degeneration.  Statistical analysis performed by Mapmanager found AhdlB6 on 
chromosome 5 and ArdB on chromosome 2 to be most significant (p < 0.00005). 
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